Epigenetic Atlas of Gastric Cancer Reveals Acid-Driven Subtype That Resists Immunotherapy
A 650-sample chromatin map exposes pre-cancerous epigenetic priming and an acid-secreting gastric cancer subtype that blocks immune response.
Summary
Researchers mapped chromatin accessibility — how tightly DNA is packed and how accessible genes are — across 650 tissue samples from 439 patients spanning normal stomach through advanced gastric cancer. They found that intestinal metaplasia, a pre-cancerous condition, already carries an epigenetic fingerprint resembling cancer, priming cells for tumor development. In advanced disease, three distinct epigenomic subtypes emerged. Two subtypes responded well to neoadjuvant immunotherapy, but a third — dubbed the pseudo-gastric subtype — was intrinsically resistant. This resistant subtype is driven by a protein called FOSL2, which activates acid-pumping enzymes that acidify the tumor environment and suppress cancer-killing CD8+ T cells. Blocking this mechanism with a drug already in clinical use — vonoprazan, a common acid blocker — restored immunotherapy sensitivity. The findings offer a new framework for stratifying gastric cancer patients and overcoming drug resistance.
Detailed Summary
Gastric cancer is one of the deadliest cancers worldwide, and a major obstacle to improving outcomes is understanding why some tumors resist immunotherapy while others respond. This landmark study addresses that problem by mapping the epigenetic landscape of gastric cancer from its earliest precancerous stages through advanced disease.
The research team constructed a large-scale chromatin accessibility atlas using 650 multistage tissue samples from 439 patients. Chromatin accessibility indicates which genomic regions are open and actively regulated, offering a powerful read-out of cell identity and disease trajectory. By tracing these patterns across the full progression from healthy gastric tissue through intestinal metaplasia, early cancer, and advanced malignancy, the team identified key epigenetic transitions driving tumorigenesis.
A striking finding was that intestinal metaplasia — a precancerous condition commonly found in patients with chronic gastritis — already displays an epigenetic profile that closely resembles cancer. This pre-cancerous priming state appears to license subsequent tumor initiation, suggesting that intervention at this stage could be particularly valuable.
In advanced gastric cancer, the atlas distinguished three epigenomic subtypes: proliferative, mesenchymal-inflammatory, and pseudo-gastric. The first two showed sensitivity to neoadjuvant immunotherapy. The pseudo-gastric subtype, however, was intrinsically resistant. Mechanistically, this subtype is driven by the transcription factor FOSL2, which upregulates H+/K+ ATPase acid transporters, creating an acidic tumor microenvironment that suppresses CD8+ T cell activity and immune killing.
Critically, the researchers demonstrated that this resistance is pharmacologically reversible. Depleting FOSL2 or administering vonoprazan — a clinically available proton pump blocker — neutralized the acidic milieu and restored immunotherapy sensitivity. These results open a practical therapeutic path for patients whose tumors currently fail immune checkpoint treatment. The study also underscores how early epigenetic changes could serve as biomarkers for cancer risk stratification. Summary is based on the abstract only.
Key Findings
- Intestinal metaplasia carries a cancer-like epigenetic signature that primes gastric cells for tumor initiation.
- Three distinct epigenomic subtypes of advanced gastric cancer were identified with different immunotherapy responses.
- The pseudo-gastric subtype resists immunotherapy via FOSL2-driven acid secretion that suppresses CD8+ T cells.
- Vonoprazan, an existing acid blocker, reversed immunotherapy resistance in the refractory subtype.
- Chromatin accessibility mapping across 650 samples reveals the full epigenetic trajectory of gastric tumorigenesis.
Methodology
The study analyzed a chromatin accessibility atlas of 650 multistage gastric tissue samples from 439 patients, spanning normal mucosa through pre-cancerous intestinal metaplasia to advanced gastric cancer. Epigenomic subtyping, transcription factor analysis, and functional experiments including FOSL2 depletion and vonoprazan treatment were used to characterize resistance mechanisms.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; methodological details, sample demographics, and statistical analyses cannot be fully evaluated. The functional reversal of immunotherapy resistance by vonoprazan requires validation in prospective clinical trials before practice change. The findings were generated predominantly in a Chinese patient cohort, and generalizability to other populations warrants further study.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: